Stephens & Co. Maintains Overweight on Cytek Biosciences, Lowers Price Target to $4.75
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Stephens & Co. analyst Mason Carrico maintains Cytek Biosciences (NASDAQ:CTKB) with a Overweight and lowers the price target from $5.5 to $4.75.
Stephens & Co. analyst Mason Carrico maintains Cytek Biosciences (NASDAQ:CTKB) with a Overweight and lowers the price target from $5.5 to $4.75.